Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

NCT01620515 is registered in ClinicalTrials.gov with Nymox Corporation as lead sponsor.

NCT NCT01620515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01620515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Lead sponsor
Nymox Corporation
Phase
Phase 2
Overall status
Completed
Start date
February 21, 2012
Completion date
October 21, 2015
Enrollment
141 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer